Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP)

Forensic Science International

Volumn 208, Issue 1-3, 2011, Pages

  Sauer, Christoph ^a   Hoffmann, Kerstin ^a   Schimmel, Ulrich ^b   Peters, Frank T ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Südharz Hospital Nordhausen   (Germany)

Author keywords

Amyl nitrite; GC MS; MPHP; Poisoning; Pyrrolidinophenone; Rhabdomyolysis

Indexed keywords

4' METHYL ALPHA PYRROLIDINOHEXANOPHENONE; AMYL NITRITE; COCAINE; DESIGNER DRUG; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGITATION; ARTICLE; BLOOD ANALYSIS; CASE REPORT; FOOT FRACTURE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH DIODE ARRAY DETECTION; HUMAN; INTOXICATION; LIQUID LIQUID EXTRACTION; LIVER TOXICITY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; MIXED MODE SOLID PHASE EXTRACTION; POWDER; PRIORITY JOURNAL; RHABDOMYOLYSIS; SILYLATION; SOLID PHASE EXTRACTION; TRIMETHYLSILYLATION; URINALYSIS;

EID: 79955466828     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.02.026     Document Type: Article

References (31)

1. Roesner P., Junge T., Fritschi G., Klein B., Thielert K., Kozlowski M. Neue synthetische Drogen: Piperazin-, Procyclidin- und alpha-Aminopropiophenonderivate. Toxichem. Krimtech. 1999, 66:81-90.
2. Springer D., Fritschi G., Maurer H.H. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 796:253-266.
3. Springer D., Peters F.T., Fritschi G., Maurer H.H. Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2002, 773:25-33.
4. Springer D., Fritschi G., Maurer H.H. Metabolism and toxicological detection of the new designer drug 4'-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 793:331-342.
5. Springer D., Fritschi G., Maurer H.H. Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 793:377-388.
6. Westphal F., Junge T., Roesner P., Fritschi G., Klein B., Girreser U. Mass spectral and NMR spectral data of two new designer drugs with an alpha-aminophenone structure: 4'-Methyl-alpha-pyrrolidinohexanophenone and 4'-methyl-alpha-pyrrolidinobutyrophenone. Forensic Sci. Int. 2007, 169:32-42.
7. Peters F.T., Meyer M.R., Fritschi G., Maurer H.H. Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2005, 824:81-91.
8. Springer D., Peters F.T., Fritschi G., Maurer H.H. New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 789:79-91.
9. Westphal F., Junge T., Roesner P., Soennichsen F., Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. Forensic Sci. Int. 2009, 190:1-8.
10. Fauquet J.P., Morel E., Demarty C., Rapin J.R. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch. Int. Pharmacodyn. Ther. 1976, 224:325-337.
11. Servin A., Fauquet J.P., Jacquot C., Rapin J.R. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem. Pharmacol. 1978, 27:1693-1694.
12. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49:1420-1432.
13. Stille G., Ackermann H., Eichenberger E., Lauener H. Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino-n-pentane HCl. Arzneim.-Forsch. 1963, 13:871-877.
14. Holliday A.R., Morris R.B., Sharpley R.P. Compound 84/F 1983 compared with d-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 1964, 6:192-200.
15. Heimann H., Lukacs G. Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans. Psychopharmacologia 1965, 8:79-90.
16. Soderholm S., Viukari N.M., Rimon R. The psychotropic effect of the Pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry. Nervenarzt 1976, 47:88-93.
17. Goldberg J., Gardos G., Cole J.O. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int. Pharmacopsychiatry 1973, 8:60-69.
18. Heinmann H., Vetter K. Clinical studies of a new psychostimulant (F-1983). Schweiz. Med. Wochenschr. 1965, 95:306-309.
19. Deniker P., Loo H., Cuche H., Roux J.M. Abuse of pyrovalerone by drug addicts. Ann. Med. Psychol. (Paris) 1975, 2:745-748.
20. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution-MS and its detectability in urine by GC-MS. J. Mass Spectrom. 2010, 45:1426-1442.
21. Meyer M.R., Peters F.T., Maurer H.H. Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin. Chem. 2010, 56:575-584.
22. Pragst F., Herzler M., Erxleben B.T. Systematic toxicological analysis by high-performance liquid chromatography with diode array detection (HPLC-DAD). Clin. Chem. Lab. Med. 2004, 42:1325-1340.
23. Maurer H.H. Methods for GC-MS. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, Part 1 2007, 4. Wiley-VCH, Weinheim. H.H. Maurer, K. Pfleger, A. Weber (Eds.).
24. Sauer C., Hoffmann K., Messerschmidt L., Meyer M.R., Maurer H.H., Peters F.T. Workup of urine samples for systematic toxicological analysis using GC-MS: acid hydrolysis/liquid-liquid extraction/acetylation versus miniaturized enzymatic hydrolysis/liquid-liquid extraction/acetylation. Ann. Toxicol. Anal. 2009, 21:33.
25. Springer D., Paul L.D., Staack R.F., Kraemer T., Maurer H.H. Identification of the cytochrome P450 enzymes involved in the metabolism of 4'-methyl-(alpha)-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab. Dispos. 2003, 31:979-982.
26. Cunningham M. Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. Intensive Crit. Care Nurs. 1997, 13:216-223.
27. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs [review]. Can. Med. Assoc. J. 2001, 165:917-928.
28. Jones A.L., Simpson K.J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 1999, 13:129-133.
29. Winslow B.T., Voorhees K.I., Pehl K.A. Methamphetamine abuse. Am. Fam. Physician 2007, 76:1169-1174.
30. Albrecht K. Intensivtherapie akuter Vergiftungen 1997, Ullstein Mosby, Berlin.
31. Bongiovanni M.S., Bradley S.L., Kelley D.M. Orthopedic trauma: critical care nursing issues. Crit. Care Nurs. Q. 2005, 28:60-71.